Cyclica Inc., a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Oncocross Co., Ltd., a biotech revolutionizing the drug development process through its unique AI approach based on transcriptome database, announce a drug discovery partnership to advance the development of oncology therapeutics. The partnership will initially focus on discovery and developing treatments for Myelofibrosis, with plans to expand to additional oncology areas.
“Combining forces with world class companies with complementary capabilities to ours is at the heart of Cyclica’s strategy. The combined strengths of the teams and platforms at Cyclica and Oncocross will lead to promising outcomes for the future of oncology medications, and we’re very enthusiastic about what this has the chance to mean for cancer patients”, shares Naheed Kurji, Co-Founder, President and CEO of Cyclica.
“We are very excited about this partnership with Cyclica, a global frontier in AI biotech space, where we put together innovative AI technologies that complement each other to yield a stronger outcome. This underlines our shared commitment to bring breakthrough solutions to cancer patients”, added Yi Rang KIM, Medical Oncologist, Founder and CEO of Oncocross.
Cyclica is an OBIO® member and presented at the OBIO Investment Summit.